Purpose Pharmacokinetic considerations in patients who have undergone Roux-en-Y gastric bypass (RYGB) are explored. Summary The prevalence of obesity, especially morbid obesity, has dramatically ...

Pharmacokinetic Considerations in Roux-en-Y Gastric Bypass Patients April Smith; Brian Henriksen; Andrew Cohen Disclosures Am J Health Syst Pharm. 2011;68 (23):2241-2247.

Introduction Previous studies have demonstrated that one anastomosis gastric bypass (OAGB) is not inferior to Roux-en-Y gastric bypass (RYGB) in treating obesity. However, high level evidence ...

Abstracts BACKGROUND: Surgical options for morbid obesity are diverse, and the Roux-en-Y gastric bypass, initially described by Fobi has gained popularity. Knowledge about the physiology of the ...